Up­dat­ed: DICE rolls on as lead oral IL-17 can­di­date meets proof-of-con­cept in PhI tri­al, send­ing shares high­er

3 years ago
R&D

Rigel steps back from sN­DA fil­ing plans for bleed­ing dis­or­der drug; NMD gives first look in­to myas­the­nia gravis ...

3 years ago
News Briefing

FDA re­veals QC is­sues at Eli Lil­ly’s man­u­fac­tur­ing site in New Jer­sey — re­port

3 years ago
FDA+
Manufacturing

Eli Lil­ly tasks Nim­bus with hit­ting a 'high-val­ue' tar­get for di­a­betes, obe­si­ty

3 years ago
Deals

An­oth­er biotech CEO de­parts, leav­ing be­hind few em­ploy­ees for PhI­II

3 years ago
People

Il­lu­mi­na con­tin­ues trek in­to drug dis­cov­ery, inks AI pact with As­traZeneca

3 years ago
Deals
AI

No speedy nasal roll­out for Ox­ford/As­traZeneca’s Covid-19 jab af­ter PhI flop

3 years ago
R&D
Pharma

PureTech, Nek­tar put an end to deal dis­cus­sions, cit­ing too much 'uncer­tain­ty'

3 years ago
Deals

A year af­ter de­but­ing with $500M, Bob Nelsen's Re­al­ly Big Neu­ro­science Com­pa­ny rais­es a re­al­ly not-as-big Se­ries B

3 years ago
Financing

Af­ter rop­ing in $175M+ at the be­gin­ning of the year, Metageno­mi opens the doors to a new man­u­fac­tur­ing site

3 years ago
Manufacturing

Gink­go inks $144M deal with Mer­ck to en­gi­neer en­zymes to im­prove in­gre­di­ent man­u­fac­tur­ing

3 years ago
Deals
Manufacturing

Michelle Mc­Mur­ry-Heath washed over­board at BIO as in­dus­try group wres­tles over its fu­ture, hunts new CEO

3 years ago
Bioregnum

Af­ter $10B in mar­ket val­ue lost, Chi­na's WuXi Bi­o­log­ics re­moved from US un­ver­i­fied list

3 years ago
China
Outsourcing

At­trac­tive M&A op­tions? An­a­lysts break down what's hot right now

3 years ago
Deals
Pharma

Up­dat­ed: In­di­an man­u­fac­tur­er un­der scruti­ny af­ter cough syrups linked to deaths in West Africa

3 years ago
Pharma
Manufacturing

Are in­cen­tives nec­es­sary to achieve tri­al di­ver­si­ty? Two re­searchers say yes

3 years ago
Pharma

As­traZeneca links cli­mate change and hu­man health in new cor­po­rate 'Science Can' cam­paign

3 years ago
Pharma
Marketing

CDER strikes back at Van­da, dis­clos­es ra­tio­nale be­hind 2019 sN­DA re­jec­tion

3 years ago
Pharma
FDA+

Sen­ate Re­pub­li­cans seek to re­peal new gov­ern­ment drug price ne­go­ti­a­tions

3 years ago
Pharma
FDA+

J&J hud­dles up with for­mer NFL play­er and sur­vivor Shan­non Sharpe for prostate can­cer push

3 years ago
Pharma
Marketing

Eu­ro­pean Com­mis­sion ac­cus­es Te­va of an­ti­com­pet­i­tive scheme as Co­pax­one sales sink

3 years ago
Pharma

FDA spurns Su­per­nus for Parkin­son's drug, not­ing ap­pli­ca­tion is­sues 'across sev­er­al ar­eas'

3 years ago
FDA+

Im­mat­ics spot­lights more ear­ly da­ta for TCR cell ther­a­py in sol­id tu­mors — now let's see if it lasts

3 years ago
R&D
Cell/Gene Tx

Af­ter two CRLs, FDA ap­proves scPhar­ma­ceu­ti­cal­s' drug-de­vice as biotech nabs $100M to fund launch

3 years ago
Financing
FDA+
First page Previous page 447448449450451452453 Next page Last page
A service from the Financial Times